Marksans Pharma slipped 1.50% to Rs 173.85 after the United States Food and Drug Administration (US FDA) issued 5 observations in Form 483 after inspecting the company's Goa-based plant.
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Marksans Pharma, one of the fastest-growing pharmaceutical companies in India, has announced that it has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC). The Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC) are bioequivalent to the reference listed drug (RLD), Mucinex Extended-Release Tablets, 600 mg and 1200 mg, of RB Health (US) LLC.
Marksans's Generic Guaifenesin Receives Approval in the U.S.
Marksans's Generic Acetaminophen, Ibuprofen Receives Approval in the U.S.
Marksans Pharma gets final USFDA nod for generic version of Famotidine tablets
Marksans Pharma Limited announces that UK MHRA has granted market authorisation to the company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.
Marksans Pharma entered into a Business Transfer Agreement with Tevapharm India yesterday, to acquire its business relating to the manufacture and supply of bulk pharma formulations in Goa, as a going concern on a slump sale basis, a statement from Marksans Pharma has notified.
Marksans Pharma on Tuesday said it has entered into an agreement with Israeli drug maker Teva's manufacturing site in Goa on a slump sale basis.